

# CITATION REPORT

List of articles citing

## Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells

DOI: 10.1016/j.xcrm.2020.100142  
Cell Reports Medicine, 2020, 1, 100142.

**Source:** <https://exaly.com/paper-pdf/76424356/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
112	Exploring the rationale for thermotherapy in COVID-19. <b>2021</b> , 38, 202-212		3
111	Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. <b>2021</b> , 296, 100701		31
110	Association between Functional Inhibitors of Acid Sphingomyelinase and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: results from an observational multicenter study.		1
109	Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19. <b>2021</b> , 22,		8
108	Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. <b>2021</b> , 26, 5199-5212		96
107	Association between Psychotropic Medications Functionally Inhibiting Acid Sphingomyelinase and reduced risk of Intubation or Death among Individuals with Mental Disorder and Severe COVID-19: an Observational Study.		5
106	Cholesterol metabolism pathways - are the intermediates more important than the products?. <b>2021</b> , 288, 3727-3745		6
105	Association between benzodiazepine receptor agonist use and increased mortality among patients hospitalized for COVID-19: results from an observational study.		1
104	Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAS) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study. <b>2021</b> , 14,		17
103	Repurposing functional inhibitors of acid sphingomyelinase (fiasmas): an opportunity against SARS-CoV-2 infection?. <b>2021</b> , 46, 1213-1219		13
102	assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells. <b>2021</b> , 2, 100356		3
101	Antidepressant and antipsychotic drugs reduce viral infection by SARS-CoV-2 and fluoxetine show antiviral activity against the novel variants in vitro.		7
100	Antihistamine and cationic amphiphilic drugs, old molecules as new tools against the COVID-19?. <b>2021</b> , 148, 110508		9
99	Coronavirus infection: An immunologists' perspective. <b>2021</b> , 93, e13043		8
98	Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19. <b>2021</b> , 12, 652688		52
97	Kite-shaped molecules block SARS-CoV-2 cell entry at a post-attachment step.		
96	Ceramide and Related Molecules in Viral Infections. <b>2021</b> , 22,		6

95	Low-dose fluvoxamine modulates endocytic trafficking of SARS-CoV-2 spike protein: a potential mechanism for anti-COVID-19 protection by antidepressants.	
94	Sphingolipids as Modulators of SARS-CoV-2 Infection. <b>2021</b> , 9, 689854	11
93	Fluoxetine pharmacokinetics and tissue distribution suggest a possible role in reducing SARS-CoV-2 titers. <b>10</b> , 477	5
92	SARS-CoV-2 infection induces the activation of tissue factor-mediated coagulation via activation of acid sphingomyelinase. <b>2021</b> , 138, 344-349	17
91	Diversity of mechanism of action of psychotropic drugs in their anti-COVID-19 properties. <b>2021</b> ,	4
90	Ceramide Metabolism Enzymes-Therapeutic Targets against Cancer. <b>2021</b> , 57,	3
89	Special issue editorial: Personalized medicine in psychiatry in the COVID-19 era: Fighting the impact of the pandemic on mental health. <b>2021</b> , 27-28, 100077	
88	Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMs) in SARS-CoV-2 Infection. <b>2021</b> , 14,	6
87	Can antidepressants unlock prescription of rimonabant in the fight against COVID-19?. <b>2021</b> ,	2
86	Association Between FIASMs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: An Observational Multicenter Study. <b>2021</b> , 110, 1498-1511	34
85	Sphingolipids: Effectors and Achilles Heels in Viral Infections?. <b>2021</b> , 10,	6
84	Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms. <b>2021</b> ,	12
83	Acid Sphingomyelinase, a Lysosomal and Secretory Phospholipase C, Is Key for Cellular Phospholipid Catabolism. <b>2021</b> , 22,	3
82	Fluoxetine hydrochloride loaded lipid polymer hybrid nanoparticles showed possible efficiency against SARS-CoV-2 infection. <b>2021</b> , 607, 121023	2
81	The Manifold Roles of Sphingolipids in Viral Infections. <b>2021</b> , 12, 715527	2
80	Psychotropics and COVID-19: An analysis of safety and prophylaxis. <b>2021</b> , 47, 564-588	1
79	Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2. <b>2021</b> , 9,	8
78	Severity of COVID-19 Patients Predicted by Serum Sphingolipids Signature. <b>2021</b> , 22,	8

77	Antiviral treatment of COVID-19: An update. <b>2021</b> ,	16
76	Sphingolipids. <b>2021</b> , 281-316	0
75	Fluoxetine pharmacokinetics and tissue distribution suggest a possible role in reducing SARS-CoV-2 titers.	6
74	Inferring a causal relationship between ceramide levels and COVID-19 respiratory distress. <b>2021</b> , 11, 20866	4
73	Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19. <b>2021</b> , 43, 633-643	1
72	The acid sphingomyelinase/ceramide system in COVID-19. <b>2021</b> ,	18
71	Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls. <b>2021</b> ,	14
70	Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. <b>2021</b> , 54, 1-6	11
69	Kite-Shaped Molecules Block SARS-CoV-2 Cell Entry at a Post-Attachment Step. <b>2021</b> , 13,	1
68	Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants. <b>2021</b> , 4, e2133090	19
67	Elevation in sphingolipid upon SARS-CoV-2 infection: possible implications for COVID-19 pathology. <b>2022</b> , 5,	2
66	Comorbid medical conditions are a key factor to understand the relationship between psychiatric disorders and COVID-19-related mortality: Results from 49,089 COVID-19 inpatients. <b>2021</b> ,	4
65	Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence. <b>2021</b> , 81, 2081-2089	6
64	Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort. <b>2021</b> , 8, e6	12
63	The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial. <b>2021</b> , 914, 174615	6
62	Neurotransmitter Transporters and Their Role in the Pharmacological Actions of Therapeutic and Abused Drugs. <b>2021</b> ,	
61	Mechanisms of action of fluvoxamine for COVID-19: a historical review.. <b>2022</b> ,	8
60	DeepMGT-DTI: Transformer network incorporating multilayer graph information for Drug-Target interaction prediction.. <b>2022</b> , 142, 105214	3

59	Strategies for drug repurposing against coronavirus targets.. <b>2022</b> , 3, 100072	1
58	COVID-19-Related Mortality Risk in People With Severe Mental Illness: A Systematic and Critical Review.. <b>2021</b> , 12, 798554	4
57	COVID-19 and its clinical severity are associated with alterations of plasma sphingolipids and enzyme activities of sphingomyelinase and ceramidase.	0
56	Risk of death in individuals hospitalized for COVID-19 with and without psychiatric disorders: an observational multicenter study in France.. <b>2022</b> ,	1
55	Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants .. <b>2021</b> , 12, 755600	6
54	Neuropsychiatric Drugs Against COVID-19: What is the Clinical Evidence?. <b>2022</b> , 55, 7-15	3
53	Antidepressant Sertraline Is a Broad-Spectrum Inhibitor of Enteroviruses Targeting Viral Entry through Neutralization of Endolysosomal Acidification.. <b>2022</b> , 14,	2
52	Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day. 10, 477	1
51	Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis-A Randomized Placebo Controlled Clinical Trial.. <b>2022</b> , 15,	0
50	Role of Protein-Lipid Interactions in Viral Entry.. <b>2022</b> , e2101264	0
49	Antidepressant drug treatment protecting from COVID-19: one more piece in the repurposing puzzle.. <b>2021</b> , 8, e20	1
48	Activation of Sphingomyelinase-Ceramide-Pathway in COVID-19 Purposes Its Inhibition for Therapeutic Strategies.. <b>2021</b> , 12, 784989	2
47	Low-Dose Fluvoxamine Modulates Endocytic Trafficking of SARS-CoV-2 Spike Protein: A Potential Mechanism for Anti-COVID-19 Protection by Antidepressants.. <b>2021</b> , 12, 787261	4
46	Hydroxyzine Use and Mortality in Patients Hospitalized for COVID-19: A Multicenter Observational Study.. <b>2021</b> , 10,	3
45	Association between benzodiazepine receptor agonist use and mortality in patients hospitalised for COVID-19: a multicentre observational study.. <b>2022</b> , 31, e18	0
44	Lung Transplantation for Adult Respiratory Distress Syndrome after SARS-CoV-2 Infection.. <b>2022</b> , 11, e23-e26	0
43	"MATH+" Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale.. <b>2022</b> , 14, 53-79	0
42	Endothelial Transcytosis in Acute Lung Injury: Emerging Mechanisms and Therapeutic Approaches.. <b>2022</b> , 13, 828093	1

41	Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study.. <b>2022</b> , 12, 90	4
40	Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19.. <b>2022</b> , 23,	0
39	Difficulty in Repurposing Selective Serotonin Reuptake Inhibitors and Other Antidepressants with Functional Inhibition of Acid Sphingomyelinase in COVID-19 Infection.. <b>2022</b> , 13, 849095	3
38	Antidepressants for COVID-19: A systematic review.. <b>2022</b> ,	0
37	Discovery of potential anti-SARS-CoV-2 drugs based on large-scale screening in vitro and effect evaluation in vivo.. <b>2021</b> , 1	2
36	Entrectinib-A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells.. <b>2021</b> , 22,	2
35	Ongoing Use of SSRIs Does Not Alter Outcome in Hospitalized COVID-19 Patients: A Retrospective Analysis.. <b>2021</b> , 11,	3
34	COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants-A Scoping Review.. <b>2022</b> , 42,	2
33	The effect of antidepressants on severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis.	
32	Comprehensive Role of SARS-CoV-2 Spike Glycoprotein in Regulating Host Signaling Pathway.. <b>2022</b> ,	0
31	Skeletal Muscle and COVID-19: The Potential Involvement of Bioactive Sphingolipids. <b>2022</b> , 10, 1068	0
30	Screening for inhibitors against SARS-CoV-2 and its variants.. <b>2022</b> ,	
29	Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment.	3
28	Antidepressant Drugs and COVID-19: A Review of Basic and Clinical Evidence. <b>2022</b> , 11, 4038	1
27	Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies. <b>2022</b> , 12,	7
26	Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2. <b>2022</b> , 12,	0
25	The Acid Ceramidase Is a SARS-CoV-2 Host Factor. <b>2022</b> , 11, 2532	2
24	Lipid balance remodelling by human positive-strand RNA viruses and the contribution of lysosomes. <b>2022</b> , 206, 105398	0

23	Antidepressant use and risk of intubation or death in hospitalized patients with COVID-19: A retrospective cohort study of clinical effectiveness. 13,	0
22	Association between SARS-CoV-2 Infection and Neuropsychiatric Manifestations. <b>2022</b> , 2, 1270-1286	0
21	Molecular Bases of Serotonin Reuptake Inhibitor Antidepressant-Attributed Effects in COVID-19: A New Insight on the Role of Bradykinins. <b>2022</b> , 12, 1487	0
20	The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis. <b>2022</b> , 17, e0267423	0
19	Prescription of selective serotonin reuptake inhibitors in COVID-19 infection needs caution. 13,	1
18	Antidepressant Use and Its Association with 28-Day Mortality in Inpatients with SARS-CoV-2: Support for the FIASMA Model against COVID-19. <b>2022</b> , 11, 5882	1
17	The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID-19 patients: A systematic review and meta-analysis. <b>2022</b> , 5,	1
16	Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day. 10, 477	0
15	In silico analysis of the antidepressant fluoxetine and related drugs at SARS-CoV-2 main protease (Mpro) and papain-like protease (PLpro). <b>2022</b> , 19,	0
14	Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection. <b>2022</b> , 14, 2417	0
13	Irradiation accelerates SARS-CoV-2 infection by enhancing sphingolipid metabolism.	0
12	Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model. <b>2022</b> , 23, 13623	0
11	Targeting the Complement Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy. <b>2022</b> , 23, 14340	0
10	In silico analysis of the antidepressant fluoxetine and similar drugs as inhibitors of the human protein acid sphingomyelinase: a related SARS-CoV-2 inhibition pathway. 1-14	2
9	Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19. 13,	0
8	Desloratadine, an FDA-approved cationic amphiphilic drug, inhibits SARS-CoV-2 infection in cell culture and primary human nasal epithelial cells by blocking viral entry. <b>2022</b> , 12,	0
7	An Overview of Fluvoxamine and its Use in SARS-CoV-2 Treatment. <b>2023</b> ,	0
6	Cholesterol-dependent molecular mechanisms contribute to cationic amphiphilic drugs prevention of silica-induced inflammation. <b>2023</b> , 102, 151310	0

- 5 Azido-Ceramides, a Tool to Analyse SARS-CoV-2 Replication and Inhibition SARS-CoV-2 Is Inhibited by Ceramides. **2023**, 24, 7281 ○
- 4 Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study. ○
- 3 Acid sphingomyelinase (ASM) and COVID-19: A review of the potential use of ASM inhibitors against SARS-CoV-2. **2023**, 41, 284-295 ○
- 2 Repurposing FIASMAs against Acid Sphingomyelinase for COVID-19: A Computational Molecular Docking and Dynamic Simulation Approach. **2023**, 28, 2989 ○
- 1 Sphingolipids in thyroid eye disease. 14, ○